Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma-Reference-Cited by-同舟云学术

Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma

Published:2023-06 Issue:6 Volume:12 Page:
ISSN:2042-6305
Container-title:Journal of Comparative Effectiveness Research
language:en
Short-container-title:J. Comp. Eff. Res.

Author:

Krishnan Amrita¹,Nooka Ajay K²,Chari Ajai³,Garfall Alfred L⁴,Martin Thomas G⁵,Nair Sandhya⁶,Lin Xiwu⁷,Qi Keqin⁸,Londhe Anil⁸,Pei Lixia⁹,Ammann Eric¹⁰,Kobos Rachel⁹,Smit Jennifer⁷,Parekh Trilok¹¹,Marshall Alexander¹⁰,Slavcev Mary¹⁰,Usmani Saad Z¹²

Affiliation:

1. Judy and Bernard Briskin Center for Multiple Myeloma Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA

2. Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA

3. Division of Hematology/Oncology, Mount Sinai School of Medicine, New York, NY 10029-5674, USA

4. Abramson Cancer Center, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

5. UCSF Helen Diller Family Comprehensive Cancer Center, Division of Hematology and Blood and Marrow Transplantation, Department of Medicine, San Francisco, CA 94143, USA

6. Janssen Pharmaceutica NV, Beerse, B-2340, Belgium

7. Janssen Global Services, Horsham, PA 19044, USA

8. Janssen Research & Development, Titusville, NJ 08560, USA

9. Janssen Research & Development, Raritan, NJ 08869, USA

10. Janssen Global Services, Raritan, NJ 08869, USA

11. Janssen Research & Development, Bridgewater, NJ 08869, USA

12. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

Abstract

Aim: We compared the effectiveness of teclistamab versus real-world physician’s choice of therapy (RWPC) in triple-class exposed relapsed/refractory multiple myeloma. Materials & methods: MajesTEC-1 eligibility criteria were applied to the RWPC cohort. Baseline covariate imbalances were adjusted using inverse probability of treatment weighting. Overall survival, progression-free survival and time to next treatment were compared. Results: After inverse probability of treatment weighting, baseline characteristics were similar between cohorts (teclistamab, n = 165; RWPC, n = 364 [766 observations]). Teclistamab treated patients had numerically better overall survival (hazard ratio [HR]: 0.82 [95% CI: 0.59–1.14]; p = 0.233) and significantly greater progression-free survival (HR: 0.43 [0.33–0.56]; p < 0.0001) and time to next treatment (HR: 0.36 [0.27–0.49]; p < 0.0001) versus the RWPC cohort. Conclusion: Teclistamab offered clinical benefit over RWPC in triple-class exposed relapsed/refractory multiple myeloma.

Funder

Janssen Global Services

Publisher

Becaris Publishing Limited

Subject

Health Policy

Link

https://becarispublishing.com/doi/pdf/10.57264/cer-2022-0186

Reference25 articles.

1. Clinical management of triple-class refractory multiple myeloma: a review of current strategies and emerging therapies;Stalker ME;Curr. Oncol.,2022

2. American Cancer Society. Cancer Facts and Figures 2020. American Cancer Society, GA, USA (2020). www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf

3. Multiple myeloma;Kyle RA;Blood,2008

4. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Multiple myeloma. Version 5.2022. www.nccn.org/guidelines/guidelines-detail?category=1&id=1445

5. Treatment patterns and outcomes in triple-class exposed patients with relapsed and refractory multiple myeloma: findings from the multinational ITEMISE study;Dhanasiri S;Clin. Ther.,2021

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2024-08

2. Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma;Expert Review of Anticancer Therapy;2024-05-26

3. Outcomes of Penta-Refractory Multiple Myeloma Patients Treated with or without BCMA-Directed Therapy;Cancers;2023-05-24